On September 6, 2022 BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, reported that members of the management team will participate in the following upcoming investor conferences (Press release, BridgeBio, SEP 6, 2022, View Source [SID1234619067]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 17th Annual BioPharma Conference, Boston, MA: September 7th at 8:50 am ET
Morgan Stanley Global Healthcare Conference, New York, NY: September 13th at 7:20 am ET
Baird Global Healthcare Conference, New York, NY: September 14th at 12:50 pm ET
H.C. Wainwright 24th Annual Global Investment Conference, New York, NY: September 14th at 11:30 am ET
Cantor Fitzgerald’s Genetic Medicines Conference, New York, NY: September 15th
Jefferies Genetic Cell and Medicine Summit, New York, NY: September 29th
Biotech South Beach, Miami, FL: September 29th
To access the live webcast of BridgeBio’s presentations, please visit the "Events" page within the Investors section of the BridgeBio website at View Source A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.